CN114949007A - 假长双歧杆菌在制备防治胰腺炎药物中的应用 - Google Patents

假长双歧杆菌在制备防治胰腺炎药物中的应用 Download PDF

Info

Publication number
CN114949007A
CN114949007A CN202210780355.1A CN202210780355A CN114949007A CN 114949007 A CN114949007 A CN 114949007A CN 202210780355 A CN202210780355 A CN 202210780355A CN 114949007 A CN114949007 A CN 114949007A
Authority
CN
China
Prior art keywords
bifidobacterium pseudolongum
preventing
sap
application
treating pancreatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210780355.1A
Other languages
English (en)
Inventor
祝荫
李雪洋
何丛
李年双
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of Nanchang University
Original Assignee
First Affiliated Hospital of Nanchang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of Nanchang University filed Critical First Affiliated Hospital of Nanchang University
Priority to CN202210780355.1A priority Critical patent/CN114949007A/zh
Publication of CN114949007A publication Critical patent/CN114949007A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供一种假长双歧杆菌在制备防治胰腺炎药物中的应用，利用不同的重症急性胰腺炎(severe acute pancreatitis，SAP)动物模型验证假长双歧杆菌在SAP中的作用，明确发现补充假长双歧杆菌可以明显减轻SAP引起的胰腺和肠道损伤。

Description

假长双歧杆菌在制备防治胰腺炎药物中的应用
技术领域
本发明涉及生物医药技术领域，特别涉及假长双歧杆菌在制备防治胰腺炎药物中的应用。
背景技术
急性胰腺炎(acute pancreatitis，AP)通常由胆道结构性梗阻、饮酒、内镜逆行胰胆管造影和药物引起，最终导致腺泡细胞死亡，诱发局部和全身炎症。大约15％-20％的患者会发展为重症急性胰腺炎(severe acute pancreatitis,SAP)。SAP过程中出现微循环损伤和低血容量，可引起肠黏膜缺血，继而再灌注损伤，导致肠屏障功能障碍和肠道菌群移位，而且肠黏膜屏障损伤导致的肠道细菌移位是引起胰腺感染坏死感染的关键环节。近年越来越多研究在动物模型中观察到肠道菌群可通过调节肠道功能进而影响AP的重症化。我们前期研究发现，无菌小鼠和抗生素预处理小鼠诱导AP后，其胰腺病理改变如水肿、炎症细胞浸润和坏死以及全身炎症反应较肠道内有菌的无特定病原体(SPF)小鼠明显减轻。
因此从调节肠道菌群失衡角度纠正肠黏膜屏障功能障碍减少肠道细菌移位对预防SAP继发胰腺坏死感染、改善患者预后具有现实指导意义。
发明内容
为了解决上述技术问题，本发明的目的是提供假长双歧杆菌的新用途，即假长双歧杆菌在制备防治胰腺炎药物中的应用。
为实现上述目的，本发明采用的技术方案是，假长双歧杆菌在制备防治胰腺炎药物中的应用。
进一步的，有效量的所述假长双歧杆菌与可与药学上可接受的载体混合制成药物组合物。
进一步的，所述药物组合物的给药形式包括前体药物、盐、酯或靶向释放制剂。
进一步的，所述前体药物为可以在生物代谢或者化学分解后释放特定短链脂肪酸的药物；
所述靶向释放制剂包含与至少一种短链脂肪酸共价键合的载体分子；
所述载体包括淀粉、树胶、寡糖或果胶类碳水化合物。
附图说明
本发明“假长双歧杆菌在制备防治胰腺炎药物中的应用”将会在以下相关实验结果中显得特别清楚，下面结合附图及实施例对本发明作进一步描述。显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动性的前提下，还可以根据这些附图获得其他的附图。
图1为SAP小鼠肠道假长双歧杆菌丰度减少的示意图；
图2为假长双歧杆菌可减轻SAP引起的肠道和胰腺损伤的示意图。
具体实施方式
下面结合附图和具体实施例，进一步阐述本发明。这些实施例应理解为仅用于说明本发明而不用于限制本发明的保护范围。在阅读了本发明记载的内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等效变化和修改同样落入本发明权利要求所限定的范围。
实施例一
一、假长双歧杆菌的SAP过程中的药效探究：
在本实施例中，假长双歧杆菌购买于ATCC(货号：25526)，培养环境为厌氧环境，温度37℃，三天传代一次。
健康小鼠40只，分为3组(对照组、雨蛙素组、雨蛙素+假长双歧杆菌组)，每组10只小鼠，分别进行如下处理：
提前给每组的小鼠灌胃一周，每日灌胃一次，每次小鼠在灌胃前将培养板上的假长双歧杆菌刮下放入脑心浸液中，吹打混匀，使用分光光度计检测细菌浓度，小鼠假长双歧杆菌灌胃浓度为5×10^9/ml。
对照组和雨蛙素组处理：雨蛙素组腹腔注射雨蛙素100ug/kg，对照组腹腔注射等量生理盐水，每小时一次，连续给药10小时，从第一次腹腔注射开始计时，24小时后处死小鼠；
各组小鼠取胰腺组织，冷冻、切片处理，染色，观察小鼠组织细胞情况，具体观察情况如图2。
本实施例通过16S rRNA检测了各组小鼠的肠道菌群结构(如图1所示)，并进一步验证了假长双歧杆菌在SAP中的作用，发现补充假长双歧杆菌可以减轻SAP引起的胰腺和肠道损伤(如图2所示)。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。

Claims (4)

1.假长双歧杆菌在制备防治胰腺炎药物中的应用。
2.根据权利要求1所述的应用，其特征在于，有效量的所述假长双歧杆菌与可与药学上可接受的载体混合制成药物组合物。
3.根据权利要求2所述的应用，其特征在于，所述药物组合物的给药形式包括前体药物、盐、酯或靶向释放制剂。
4.根据权利要求3所述的应用，其特征在于，所述前体药物为可以在生物代谢或者化学分解后释放特定短链脂肪酸的药物；
所述靶向释放制剂包含与至少一种短链脂肪酸共价键合的载体分子；
所述载体包括淀粉、树胶、寡糖或果胶类碳水化合物。
CN202210780355.1A 2022-07-04 2022-07-04 假长双歧杆菌在制备防治胰腺炎药物中的应用 Pending CN114949007A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210780355.1A CN114949007A (zh) 2022-07-04 2022-07-04 假长双歧杆菌在制备防治胰腺炎药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210780355.1A CN114949007A (zh) 2022-07-04 2022-07-04 假长双歧杆菌在制备防治胰腺炎药物中的应用

Publications (1)

Publication Number Publication Date
CN114949007A true CN114949007A (zh) 2022-08-30

Family

ID=82968572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210780355.1A Pending CN114949007A (zh) 2022-07-04 2022-07-04 假长双歧杆菌在制备防治胰腺炎药物中的应用

Country Status (1)

Country Link
CN (1) CN114949007A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106617096A (zh) * 2017-02-15 2017-05-10 中国农业大学 一种增强胰岛功能的双歧杆菌及其应用
WO2019243563A1 (en) * 2018-06-22 2019-12-26 Synformulas Gmbh Non-viable bifidobacterium bifidum bacteria and uses thereof
US20200113951A1 (en) * 2017-02-06 2020-04-16 New York University Methods and compositions for treating and diagnosing pancreatic cancers
CN111110703A (zh) * 2020-01-13 2020-05-08 华中农业大学 动物双歧杆菌及其制备的复合菌制剂在制备治疗或预防禽流感病毒感染的药物中的应用
CN111996153A (zh) * 2020-09-18 2020-11-27 南京益瑞兰生物科技有限公司 一种短双歧杆菌及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200113951A1 (en) * 2017-02-06 2020-04-16 New York University Methods and compositions for treating and diagnosing pancreatic cancers
CN106617096A (zh) * 2017-02-15 2017-05-10 中国农业大学 一种增强胰岛功能的双歧杆菌及其应用
WO2019243563A1 (en) * 2018-06-22 2019-12-26 Synformulas Gmbh Non-viable bifidobacterium bifidum bacteria and uses thereof
CN111110703A (zh) * 2020-01-13 2020-05-08 华中农业大学 动物双歧杆菌及其制备的复合菌制剂在制备治疗或预防禽流感病毒感染的药物中的应用
CN111996153A (zh) * 2020-09-18 2020-11-27 南京益瑞兰生物科技有限公司 一种短双歧杆菌及其应用

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
KEN KAMATA等: "Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells", vol. 31, no. 12, pages 795 - 809 *
ROBERT MEMBA等: "The potential role of gut microbiota in pancreatic disease: A systematic review", vol. 17, no. 6, pages 867 - 874 *
SMRUTI PUSHALKAR等: "The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression", vol. 8, no. 4, pages 403 - 416, XP055759534, DOI: 10.1158/2159-8290.CD-17-1134 *
YUE XIAO等: "Colonized Niche, Evolution and Function Signatures of Bifidobacterium pseudolongum within Bifidobacterial Genus", vol. 10, no. 10 *
周翔等: "肠道微生态与胰腺炎的研究进展", vol. 24, no. 02, pages 222 - 228 *
彭国林等: "双歧杆菌预防重症急性胰腺炎感染疗效观察", no. 3, pages 156 *
石屏屏等: "双歧杆菌三联活菌胶囊对重症急性胰腺炎患者炎症因子及肠黏膜屏障功能的影响", vol. 21, no. 11, pages 1489 - 1495 *
赵乃昕等: "医学细菌名称及分类鉴定", 山东大学出版社, pages: 77 *
陈智等: "双歧杆菌制剂对急性重症胰腺炎感染的治疗作用", vol. 14, no. 04, pages 209 - 210 *

Similar Documents

Publication Publication Date Title
Zhanel et al. The glycylcyclines: a comparative review with the tetracyclines
Guo et al. Vanillin protects the blood–milk barrier and inhibits the inflammatory response in LPS-induced mastitis in mice
CN112972379B (zh) 一种加米霉素乳剂及制备方法与在防治猪回肠炎方面的应用
CN113527368B (zh) 化合物、抗癌药物的制备方法和用途
CN110960539A (zh) 桑皮苷a及其衍生物在制备保护肠道屏障的药物中的应用
Jung et al. What should be considered on design of a colon-specific prodrug?
CN108402371A (zh) 一种适合中老年便秘人群服用的益生元组合物
CN107865964A (zh) 低渗性脂肪分解组合物及其制备方法
Farber Clinical and biological studies with actinomycins
CN101849969A (zh) 产酪酸有益菌在制备防治重症疾病肠道屏障损伤及损伤后并发症制剂中的应用
CN114949007A (zh) 假长双歧杆菌在制备防治胰腺炎药物中的应用
US20160339057A1 (en) Novel composition method of using the same for the treatment of lyme disease
CN106974908A (zh) 含有hdac抑制剂和ire1抑制剂的药物组合物及用途
KR102401604B1 (ko) 데스메틸클로자핀의 새로운 용도
CN107823204B (zh) 一种吉米沙星的新用途
CN114522158B (zh) 用于制备治疗肝癌药物的代谢物及其应用
Lechevalier The 25 years of neomycin
CN108126201B (zh) 肠道菌抗生素在制备防治化疗并发症药物中的应用
CN115068457A (zh) 短链脂肪酸在制备治疗急性胰腺炎药物中的应用
CN113209149A (zh) 米托蒽醌与人参总皂苷联合用药在制备治疗胃癌药物中的应用
EP3888649A1 (en) Use of geranylflavone a in preparation of drug for promoting healing of wounds
CN107412733B (zh) 一种高活性注射用脑蛋白水解物（ii）组合物及其应用
CN109620848B (zh) 一种乳酸乳球菌的应用
CN1256092C (zh) 注射用甲基红霉素制剂
CN112755023B (zh) 一种新型表观遗传因子抑制剂2800z在制备肝癌药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination